Ernest Nadal
YOU?
Author Swipe
View article: Characterization of pretreatment cachexia through cytokine and nutritional analysis in lung cancer: the Marató cohort
Characterization of pretreatment cachexia through cytokine and nutritional analysis in lung cancer: the Marató cohort Open
Background Cancer-associated cachexia, a frequent complication of solid tumours, is not recorded in cancer registries. Cachexia affects patients diagnosed with non-small cell lung cancer (NSCLC); however, a detailed characterization of nut…
View article: ATF4 and ATF6 produce diverse transcriptional signatures affecting metabolic genes and cell death under glucose deprivation
ATF4 and ATF6 produce diverse transcriptional signatures affecting metabolic genes and cell death under glucose deprivation Open
Tumours grow faster than the local vasculature, resulting in a shortage of oxygen and nutrients. Among nutrients reduced in the tumor microenvironment, glucose is essential for tumour growth and survival. To explore how lung cancer cells c…
View article: 755 CXCL13 as a biomarker of primary resistance to immunotherapy in non-small cell lung cancer
755 CXCL13 as a biomarker of primary resistance to immunotherapy in non-small cell lung cancer Open
View article: 734 Tertiary lymphoid structures as hallmarks of response to neoadjuvant chemoimmunotherapy in locally advanced non-small cell lung cancer NADIM trial
734 Tertiary lymphoid structures as hallmarks of response to neoadjuvant chemoimmunotherapy in locally advanced non-small cell lung cancer NADIM trial Open
View article: Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry Open
Background With nearly one-third of patients with advanced non-small cell lung cancer (NSCLC) and PD-L1 Tumor Proportion Score≥50% surviving beyond 5 years following first-line pembrolizumab, long-term outcomes challenge traditional paradi…
View article: Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC): 2nd Spanish Lung Cancer Group (GECP) expert consensus statement
Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC): 2nd Spanish Lung Cancer Group (GECP) expert consensus statement Open
Updated suggestions were developed for the most relevant situations in the treatment of patients with early-stage and locally advanced NSCLC. These suggestions will support clinical decision-making in daily practice. This paper presents th…
View article: Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)
Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial) Open
Perioperative chemoimmunotherapy has significantly improved survival rates for non-small cell lung cancer (NSCLC). However, current tissue biomarkers remain inadequate, underscoring the need for more sensitive and accessible alternatives t…
View article: Matching-adjusted indirect comparison of selpercatinib and pralsetinib in <i>RET</i> fusion–positive non–small cell lung cancer
Matching-adjusted indirect comparison of selpercatinib and pralsetinib in <i>RET</i> fusion–positive non–small cell lung cancer Open
Outcomes were similar; however, PFS was significantly prolonged with selpercatinib, with fewer grade ≥ 3 TRAEs.
View article: Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer
Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer Open
Molecular determinants of KRAS(G12C)inhibitor efficacy in KRASG12C-mutated non-small-cell lung cancer (NSCLC) remain poorly characterized. Here we report one of the largest integrated analyses to date of sotorasib clinical effic…
View article: Emerging Role of Targeted Therapies Combined With Radiotherapy in Inoperable Stages I to III NSCLC: A Review From the IASLC ART Subcommittee
Emerging Role of Targeted Therapies Combined With Radiotherapy in Inoperable Stages I to III NSCLC: A Review From the IASLC ART Subcommittee Open
Precision oncology has transformed the management of NSCLC by tailoring treatment to the specific genetic alterations driving oncogenesis. Targeted therapies, such as tyrosine kinase inhibitors, have been found to dramatically improve surv…
View article: Legends to supplementary figures and tables from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition
Legends to supplementary figures and tables from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition Open
Contains the legends for all the supplementary figures and legends
View article: Supplementary methods and materials from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition
Supplementary methods and materials from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition Open
Supplementary methods and materials
View article: Supplementary Table S2 from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition
Supplementary Table S2 from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition Open
Supplementary Table S2
View article: Supplementary figures from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition
Supplementary figures from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition Open
Supplementary Figure 1, 2,3 4,5
View article: Supplementary Table 1 from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition
Supplementary Table 1 from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition Open
Supplementary Table 1A, B, C, D and E
View article: Data from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition
Data from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition Open
Purpose: We aimed to maximize the performance of detecting genetic alterations in lung cancer using high-throughput sequencing for patient-derived xenografts (PDXs).Experimental Design: We undertook an integrated RNA and whol…
View article: Supplementary Table S3 from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition
Supplementary Table S3 from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition Open
Supplementary Table S3
View article: Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study
Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study Open
The prevalence of EGFR mutations in early stage (IA-IIIB), resectable, non-squamous NSCLC observed in our study is consistent with that reported in advanced NSCLC in Spain. Molecular testing is crucial in early-stage NSCLC and can b…
View article: Observational study on the safety and effectiveness of SARS-CoV-2 vaccination in patients with lung cancer
Observational study on the safety and effectiveness of SARS-CoV-2 vaccination in patients with lung cancer Open
View article: Preventing Infusion-Related Reactions With Intravenous Amivantamab—Results From SKIPPirr, a Phase 2 Study: A Brief Report
Preventing Infusion-Related Reactions With Intravenous Amivantamab—Results From SKIPPirr, a Phase 2 Study: A Brief Report Open
Prophylaxis with 8 mg oral dexamethasone meaningfully reduced IRRs and can be readily implemented in clinical practice.
View article: Efficacy and safety of lorlatinib in patients with ALK- and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain
Efficacy and safety of lorlatinib in patients with ALK- and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain Open
We evaluated the efficacy and safety of lorlatinib in ALK- and ROS1-positive NSCLC patients within a compassionate use program in Spain. Among 61 ALK-positive patients, including 59 % with brain metastasis and 85.2 % treated with at least …
View article: Efficacy and Safety of Bintrafusp Alfa Evaluated in a Phase Ii Single-Arm Clinical Trial in Previously Treated Advanced Pleural Mesothelioma
Efficacy and Safety of Bintrafusp Alfa Evaluated in a Phase Ii Single-Arm Clinical Trial in Previously Treated Advanced Pleural Mesothelioma Open
View article: Neoadjuvant Therapy in Robotic Lung Surgery: Elevating Surgical Complexity Without Compromising Outcomes
Neoadjuvant Therapy in Robotic Lung Surgery: Elevating Surgical Complexity Without Compromising Outcomes Open
Background: Neoadjuvant therapy, particularly the combination of chemotherapy and immunotherapy, has become standard in treating locally advanced non-small cell lung cancer (NSCLC). While this approach improves pathologic responses, its ef…
View article: Supplementary Figure S11 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Supplementary Figure S11 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial Open
Supplementary Figure S11. Overall survival by EGFR del19/L858R mutational status at week 9 (N=107) - landmark analysis (post 9-week time).
View article: Supplementary Figure S3 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Supplementary Figure S3 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial Open
Supplementary Figure S3. EGFR T790M mutational status (MD/MND) by treatment arm at baseline (N=136), week 9 (N=110) and progression (N=65).
View article: Supplementary Figure S9 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Supplementary Figure S9 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial Open
Supplementary Figure S9. Overall survival for the N=136 patients constituting the biomarker analysis cohort, by baseline mutational status of (A) EGFR T790M (B) TP53.
View article: Supplementary Figure S8 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Supplementary Figure S8 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial Open
Supplementary Figure S8. Progression-free survival by EGFR del19/L858R mutational status at week 9 (N=105) - landmark analysis (post 9-week time).
View article: Supplementary Appendix S1 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Supplementary Appendix S1 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial Open
List of ETOP 10-16 BOOSTER collaborators
View article: Supplementary Figure S6 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Supplementary Figure S6 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial Open
Supplementary Figure S6. Association of EGFR T790M MAF with time, based on N=136 baseline, N=110 week 9 and N=65 progression samples.
View article: Supplementary Figure S10 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Supplementary Figure S10 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial Open
Supplementary Figure S10. Overall survival by EGFR T790M mutational status at week 9 (N=106) - landmark analysis (post 9-week time).